In the present study, the anti-HCC effect of combined therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 were measured both in vitro on human Hep3B and HuH7 cell lines; which are well differentiated human hepatocyte-derived cellular carcinoma cell lines commonly used in studying liver cancer and its potential therapies [32, 36], and in vivo on an orthotopic model of human HCC established by intrahepatic implantation of Hep3B into the liver lobes of immunodeficient nude mice. Here, TNFSF10 is linked to hepatocellular carcinoma.